# US 11,028,104 B2 · Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,028,104 B2
- Document ID: US11028104B2
- Status: Granted
- Kind: B2
- Application number: 16/867,835
- Filed: 2020-05-06
- Published: 2020-08-20
- Granted: 2021-06-08
- Earliest claimed: 2016-07-28
- Assignees: Max-Delbruck-Centrum fur Molekulare Medizin; Forschungsverbund Berlin E.V.
- Applicants: Max-DelbrüCk-Centrum FüR Molekulare Medizin; Forschungsverbund Berlin E.V.
- Inventors: Michael Bader; Edgar Specker; Susann Matthes; Anja Schütz; Keven Mallow; Maik Grohmann; Marc Nazaré
- Web page: https://patentgrep.com/patent/US11028104B2

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.

## Claims

### Claim 1

A method for treating a serotonin-related disease or disorder comprising administering to a patient in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the serotonin-related disease or disorder is Crohn's disease, ulcerative colitis, inflammatory bowel disease, or systemic sclerosis, and wherein the compound has the Formula (I):
wherein:
R1 and R2 are each an optionally substituted group independently selected from the group consisting of a hydrogen (—H), one of a (C1-C10)-alkyl group, a (C2-C10)-alkenyl group, a (C2-C10)-alkynyl group, a (C6-C14)-aryl group, a (C6-C14)-heteroaryl group, a (C7-C15)-alkyl-arylene group, a (C7-C15)-alkyl-heteroarylene group, a (C8-C15)-alkenyl-arylene group, a (C8-C15)-alkenyl-heteroarylene group, a (C8-C15)-alkynyl-arylene group, a (C8-C15)-alkynyl-heteroarylene group, a (C7-C15)-aryl-alkylene group, a (C7-C15)-heteroaryl-alkylene group, a (C8-C15)-aryl-alkenylene group, a (C8-C15)-heteroaryl-alkenylene group, a (C8-C15)-aryl-alkynylene group, and a (C8-C15)-heteroaryl-alkynylene group, wherein alkyl, alkenyl, alkynyl, alkylene, alkenylene, and alkynylene, when present in the aforementioned groups, may comprise one or more bivalent groups substituting a carbon moiety —C— and the one or more bivalent groups is selected from the group consisting of —O—, —S—, —S(O)—, —SO2—, —N═, —C(O)—, —C(O)O—, —OC(O)—, —C(O)N(R)—, —N(R)C(O)—, —OC(O)N(R)—, —N(R)C(O)O—, —N(R)C(O)N(R)—, (C3-C12)-heterocyclic alkylene, and (C3-C12)-heterocyclic alkenylene;
R3 is a group independently selected from the group consisting of hydrogen (—H), fluoro (—F), bromo (—Br), chloro (—Cl), a hydroxyl group (—OH), an acyl group (—C(O)R), a carboxyl group (—C(O)OH), a carboxy ester group (—CO2R), an alkoxy group (—OR), an aldehyde group (—C(O)H), a trihalide methyl ester group (—OCX3), a primary amine group (—NH2), a secondary amine group (—N(R)H), a tertiary amine group (—NR(R′)), an amide group (—N(R)—C(O)—R), an imide group (—C(O)—N(R)—C(O)—R′), a carbamate group (—N(R)—C(O)—OR′), a carboxamide group (—C(O)N(R)R′), a carbimide group (—N(R)—C(O)—N(R′)R″), a primary ketimine group —C(R)═NH, a secondary ketimine group (—C(R)═NR′), a nitrile group (—CN), an isonitrile group (—NC), a nitroxy group (—ONO), a nitro group (—NO2), a nitrate group (—ONO2), a nitroso group (—NO), a cyanate group (—OCN), an isocyanate group (—NCO), a sulfhydryl group (—SH), a sulfide group (—SR), a sulfurtrihalide group (—SX3), a sulfurpentahalide group (—SX5), a sulfinyl group (—S(O)R), a sulfonyl group (—SO2R), a sulfino group (—SO2H), and a sulfo group (—SO3H), or an optionally substituted and/or optionally linked group selected from the group consisting of a (C1-C10)-alkyl group, a (C2-C10)-alkenyl group, a (C2-C10)-alkynyl group, a (C6-C14)-aryl group, a (C6-C14)-heteroaryl group, a (C7-C15)-alkyl-arylene group, a (C7-C15)-alkyl-heteroarylene group, a (C8-C15)-alkenyl-arylene group, a (C8-C15)-alkenyl-heteroarylene group, a (C8-C15)-alkynyl-arylene group, a (C8-C15)-alkynyl-heteroarylene group, a (C7-C15)-aryl-alkylene group, a (C7-C15)-heteroaryl-alkylene group, a (C8-C15)-aryl-alkenylene group, a (C8-C15)-heteroaryl-alkenylene group, a (C8-C15)-aryl-alkynylene group, and a (C8-C15)-heteroaryl-alkynylene group, wherein alkyl, alkenyl, alkynyl, alkylene, alkenylene, or alkynylene, when present in the aforementioned groups of R3, may comprise one or more bivalent groups substituting a carbon moiety —C— and the one or more bivalent groups is selected from the group consisting of —O—, —S—, —S(O)—, —SO2—, —N═, —N(R)—, —C(O)—, —C(O)O—, —OC(O)—, —C(O)N(R)—, —N(R)C(O)—, —OC(O)N(R)—, —N(R)C(O)O—, —N(R)C(O)N(R)—, (C3-C12)-heterocyclic alkylene, and (C3-C12)-heterocyclic alkenylene, and wherein X is a halide;
Q is selected from the group consisting of hydrogenated carbon, non-hydrogenated carbon, hydrogenated nitrogen, and non-hydrogenated nitrogen, oxygen, sulfur, —*CH2—CH(R′″)—, —*CH═C(R′″)—, —*CH2—O—, and —*CH2—N(R′″)—, wherein:
R′″ represents hydrogen, a methyl group, an ethyl group, a cyclopropyl group,
a —CH2-cyclopropyl group, or a halogen; and
the carbon marked with an asterisk is covalently linked to the imidazole group set forth in Formula (I);
Z is selected from the group consisting of hydrogenated carbon, and non-hydrogenated carbon, hydrogenated nitrogen, non-hydrogenated nitrogen, oxygen and sulfur;
the ring member A is a saturated, unsaturated, or aromatic ring;
the substituents for the optionally substituted groups are selected from the group consisting of a fluoro (—F), a bromo (—Br), a chloro (—CI), a hydroxyl group (—OH), a (C1-C3)-alkyl group, a (C2-C3)-alkenyl group, an acyl group (—C(O)R), a carboxyl group (—C(O)OH), a carboxylate group (—C(O)O−), a carboxy ester group (—CO2R), an alkoxy group (—OR), an aldehyde group (—C(O)H), a trihalide methyl ester group (—OCX3), a primary amine group (—NH2), a secondary amine group (—N(R)H), a tertiary amine group (—NR(R′)), an amide group (—N(R)—C(O)—R), an imide group (—C(O)—N(R)—C(O)—R′), a carbamate group (—N(R)—C(O)—OR′), a carboxamide group (—C(O)N(R)(R′)), a carbimide group (—N(R)—C(O)—N(R′)R″), a primary ketimine group(—C(R)═NH), a secondary ketimine group (—C(R)═NR′), a nitrile group (—CN), an isonitrile group (—NC), a nitroxy group (—ONO), a nitro group (—NO2), a nitrate group (—ONO2), a nitroso group (—NO), a cyanate group (—OCN), an isocyanate group (—NCO), a sulfhydryl group (—SH), a sulfide group (—SR), a sulfurtrihalide group (—SX3), a sulfurpentahalide group (—SX5), a sulfinyl group (—S(O)R), a sulfonyl group (—SO2R), a sulfino group (—SO2H), a sulfo group (—SO3H), and combinations thereof, and wherein X is a halide;
R is independently hydrogen, a (C1-C3)-alkyl group, or a (C2-C3)-alkenyl group;
R′ is independently hydrogen, a (C1-C3)-alkyl group, or a (C2-C3)-alkenyl group; and
R″ is independently hydrogen, a (C1-C3)-alkyl group, or a (C2-C3)-alkenyl group.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the compound or a pharmaceutical acceptable salt thereof is administered to the patient in a pharmaceutical preparation.

### Claim 3 (depends on 1)

The method according to claim 1, wherein at least one of R1 and R2 is not hydrogen.

### Claim 4 (depends on 1)

The method according to claim 1, wherein R1 is selected from the group consisting of an optionally substituted linear, branched, and cyclic (C1-C5)-alkyl group.

### Claim 5 (depends on 1)

The method according to claim 1, wherein R2 is selected from the group consisting of an optionally substituted (C5-C13)-aryl, (C5-C13)-heteroaryl, (C6-C13)-alkyl-arylene, (C6-C13)-alkyl-heteroarylene, (C6-C13)-alkenyl-arylene, (C6-C13)-alkenylheteroarylene, (C6-C13)-alkynyl-arylene, (C6-C13)-alkynyl-heteroarylene, (C6-C13)-aryl-alkylene, (C6-C13)-heteroaryl-alkylene, (C6-C13)-aryl-alkenylene, (C6-C13)-heteroaryl-alkenylene, (C6-C13)-aryl-alkynylene, and (C6-C13)-heteroaryl-alkynylene.

### Claim 6 (depends on 1)

The method according to claim 1, wherein R2 is a group defined by chemical formula (Ia)
—R5—Ar (Ia),
wherein:
R5 is (C0-C3)-alkylene, and
Ar is an optionally substituted (C5-C12)-aryl or (C5-C12)-heteroaryl.

### Claim 7 (depends on 1)

The method according to claim 1, wherein:
R3 is hydrogen, fluorine, chlorine, bromine, amine, amide, carbonitrile, optionally substituted (C1-C10)-alkyl, optionally substituted saturated or unsaturated(C5-C6)-heterocycle, optionally substituted (C2-C10)-alkenyl, or optionally substituted (C1-C5)-alkoxy; the optionally substituted (C1-C10)-alkyl, when present, optionally comprises one or more bivalent groups; and
the optionally substituted (C2-C10)-alkenyl, when present, optionally comprises one or more bivalent groups.

### Claim 8 (depends on 1)

The method according to claim 1, wherein Q is selected from the group consisting of ethylene (—CH2-CH2-), ethenylene (—CH═CH—), and sulfur (—S—).

### Claim 9 (depends on 1)

The method according to claim 1, wherein Z is selected from the group consisting of hydrogenated carbon, non-hydrogenated carbon, hydrogenated nitrogen, and non-hydrogenated nitrogen.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of one of the compounds represented by chemical Formulas (I-1) to (I-39):

### Claim 11 (depends on 1)

The method according to claim 1, wherein the compound or a pharmaceutically acceptable salt thereof is disposed in a medicament.